Document:

EX-4.3

 Exhibit 4.3 

WARRANT AGENCY AGREEMENT 

WARRANT AGENCY AGREEMENT (“Agency Agreement”) made as of January [●], 2017 (“Issuance Date”), between
Provectus Biopharmaceuticals, Inc., a Delaware corporation, with offices at 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931 (the “Company”), and Broadridge Corporate Issuer Solutions, Inc., with offices at 1717 Arch
Street, Suite 1300, Philadelphia, Pennsylvania 19103 (the “Warrant Agent”). 
 WHEREAS, the Company is distributing to
holders of its common stock, par value $0.001 per share (the “Common Stock”), and holders of the Company’s class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (“Listed Warrants”)
subscription rights (the “Rights”) to purchase up to an aggregate of 19,662,782 units (the “Units”), each Unit consisting of four (4) shares of Common Stock (the “Shares”) and one-half (1/2) a share
of Series C Convertible Preferred Stock (the “Preferred Stock”); and 
 WHEREAS, for certain investors whose subscriptions
may result in the purchaser beneficially owning more than 4.99% of the Company’s outstanding Common Stock, such investors may elect to receive in lieu of shares of Common Stock, certain pre-funded warrants (the “Pre-Funded
Warrants”) to purchase the same amount of shares of Common Stock at an exercise price equal to $0.0025 per share, and the subscription price per Unit for any such electing investors will be reduced to $[●] (which equals the
Subscription Price for the other Units sold, less the $0.0025 exercise price for each Pre-Funded Warrant); and 
 WHEREAS, the Company has
filed with the U.S. Securities and Exchange Commission a Registration Statement, No. 333-213986 on Form S-1 (as the same may be amended from time to time, the “Registration Statement”) for the registration, under the Securities Act
of 1933, as amended (the “Act”), in part, of the Rights, the Units, the Shares, the Pre-Funded Warrants and the Common Stock issuable upon exercise of the Pre-Funded Warrants (the “Warrant Shares”), and such
Registration Statement was declared effective on January [●], 2017; and 
 WHEREAS, the Company desires the Warrant Agent to act on
behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange and exercise of the Pre-Funded Warrants; and 

WHEREAS, the Company desires to provide for the form and provisions of the Pre-Funded Warrants, the terms upon which they shall be issued and
exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Pre-Funded Warrants; and 

WHEREAS, all acts and things have been done and performed which are necessary to make the Pre-Funded Warrants, when executed on behalf of the
Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agency Agreement. 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows: 

1. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Pre-Funded
Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agency Agreement. 

  
 1 

 2. Pre-Funded Warrants. 

2.1 Form of Warrant. Each Pre-Funded Warrant shall be issued in registered form only, shall be in substantially the form of Exhibit
A hereto, the provisions of which are incorporated herein, and shall be signed by, or bear the facsimile signature of, the Chief Executive Officer, President, Chief Financial Officer or Treasurer, Secretary or Assistant Secretary of the Company.
In the event the person whose facsimile signature has been placed upon any Pre-Funded Warrant shall have ceased to serve in the capacity in which such person signed the Pre-Funded Warrant before such Pre-Funded Warrant is issued, it may be issued
with the same effect as if he or she had not ceased to be such at the date of issuance. All of the Pre-Funded Warrants shall initially be represented by one or more book-entry certificates (each a “Book-Entry Warrant Certificate”).

 2.2. Effect of Countersignature. Unless and until countersigned by the Warrant Agent pursuant to this Agency Agreement, a
Pre-Funded Warrant shall be invalid and of no effect and may not be exercised by the holder thereof. 
 2.3. Registration.

2.3.1. Warrant Register. The Warrant Agent shall maintain books (“Warrant Register”), for the registration of
original issuance and the registration of transfer of the Pre-Funded Warrants. Upon the initial issuance of the Pre-Funded Warrants, the Warrant Agent shall issue and register the Pre-Funded Warrants in the names of the respective holders thereof in
such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. To the extent the Pre-Funded Warrants are eligible for the book entry and depository services of The Depository Trust Company
(“DTC eligible”) as of the Issuance Date, all of the Pre-Funded Warrants shall be represented by one or more Book-Entry Warrant Certificates deposited with The Depository Trust Company (the “Depository”) and
registered in the name of Cede & Co., a nominee of the Depository. Ownership of beneficial interests in the Book-Entry Warrant Certificates shall be shown on, and the transfer of such ownership shall be effected through, records maintained (i)
by the Depository or its nominee for each Book-Entry Warrant Certificate; (ii) by institutions that have accounts with the Depository (such institution, with respect to a Pre-Funded Warrant in its account, a “Participant”); or (iii)
directly on the book-entry records of the Warrant Agent with respect only to owners of beneficial interests represented by such direct registration. 

If the Pre-Funded Warrants are not DTC eligible as of the Issuance Date or the Depository subsequently ceases to make its book-entry
settlement system available for the Pre-Funded Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement within ten (10) days after the Depository ceases to make its book-entry settlement
available. In the event that the Company does not make alternative arrangements for book-entry settlement within ten (10) days or the Pre-Funded Warrants are not eligible for, or it is no longer necessary to have the Pre-Funded Warrants available
in, book-entry form, the Warrant Agent shall provide written instructions to the Depository to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the
Depository definitive certificates (“Warrant Certificates”) in physical form evidencing such Pre-Funded Warrants. Such Warrant Certificates shall be in substantially the form annexed hereto as Exhibit A. 

  
 2 

 2.3.2. Beneficial Owner; Registered Holder. The term “beneficial owner” shall
mean any person in whose name ownership of a beneficial interest in the Pre-Funded Warrants evidenced by a Book-Entry Warrant Certificate is recorded in the records maintained by the Depository or its nominee. Prior to due presentment for
registration of transfer of any Pre-Funded Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Pre-Funded Warrant shall be registered upon the Warrant Register (“registered holder”), as the
absolute owner of such Pre-Funded Warrant and of each Pre-Funded Warrant represented thereby (notwithstanding any notation of ownership or other writing on the Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the
purpose of any exercise thereof and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. 

2.4. Separate Transferability of Pre-Funded Warrants. The Pre-Funded Warrants will be issued as a separate security from any Common
Stock issued concurrently in the offering of the Pre-Funded Warrants and will be separately transferable immediately upon issuance. 
 2.5
Uncertificated Pre-Funded Warrants. Notwithstanding the foregoing and anything else herein to the contrary, the Pre-Funded Warrants may be issued in uncertificated form. 

3. Terms and Exercise of Pre-Funded Warrants. 

3.1 Terms of Pre-Funded Warrants. The form of Pre-Funded Warrant attached hereto as Exhibit A, the provisions of which are
incorporated herein and which govern all of the substantive terms of the Pre-Funded Warrant. To the extent any term or provision herein is inconsistent with Exhibit A, the terms and provisions of Exhibit A shall control. 

3.2. Exercise of Pre-Funded Warrants. 

3.2.1. Exercise and Payment. A registered holder may exercise a Pre-Funded Warrant by delivering, at any time and from time to time on
or after the Original Issue Date and through and including 5:00 P.M. Eastern time on the Expiration Date, to the Warrant Agent at its corporate trust department (i) the Warrant Certificate evidencing the Pre-Funded Warrants to be exercised, or, in
the case of a Book-Entry Warrant Certificate, the Pre-Funded Warrants to be exercised (the “Book-Entry Pre-Funded Warrants”) shown on the records of the Depository to an account of the Warrant Agent at the Depository designated for
such purpose in writing by the Warrant Agent to the Depository from time to time, (ii) an exercise notice, in the form attached as Schedule 1 to the Pre-funded Warrant (the “Exercise Notice”), completed and duly signed, and (iii)
the Exercise Price for each Pre-Funded Warrant to be exercised either in lawful money of the United States of America by certified or official bank check, by bank wire transfer in immediately available funds, or by a “net share
exercise” pursuant to Section 10 of the Pre-Funded Warrant, and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions in the Pre-funded Warrant) is an “Exercise
Date.” 
 If any of (A) the Warrant Certificate or the Book-Entry Pre-Funded Warrants, (B) the Exercise Notice, or (C) the
Exercise Price therefor, is received by the Warrant Agent after 5:00 P.M., Philadelphia, Pennsylvania time, on the specified Exercise Date, the Pre-Funded Warrants will be deemed to be received and exercised on the business day next

  
 3 

 
succeeding the Exercise Date. If the date specified as the Exercise Date is not a business day, the Pre-Funded Warrants will be deemed to be received and exercised on the next succeeding day that
is a business day. If the Pre-Funded Warrants are received or deemed to be received after the Expiration Date, the exercise thereof will be null and void and any funds delivered to the Warrant Agent will be returned to the registered holder or
Participant, as the case may be, as soon as practicable. In no event will interest accrue on funds deposited with the Warrant Agent in respect of an exercise or attempted exercise of Pre-Funded Warrants. The validity of any exercise of Pre-Funded
Warrants will be determined by the Company in its sole discretion and such determination will be final and binding upon the registered holder or Participant, as applicable, and the Warrant Agent. Neither the Company nor the Warrant Agent shall have
any obligation to inform a registered holder or the Participant, as applicable, of the invalidity of any exercise of Pre-Funded Warrants. 

The Warrant Agent shall deposit all funds received by it in payment of the Exercise Price in the account of the Company maintained with the
Warrant Agent for such purpose and shall advise the Company via telephone at the end of each day on which funds for the exercise of the Pre-Funded Warrants are received of the amount so deposited to its account. The Warrant Agent shall promptly
confirm such telephonic advice to the Company in writing. 
 3.2.2. Issuance of Certificates. The Warrant Agent shall, by 11:00 A.M.
Philadelphia, Pennsylvania time on the business day following the Exercise Date of any Pre-Funded Warrant, advise the Company or the transfer agent and registrar in respect of (a) the Pre-Funded Warrant Shares issuable upon such exercise as to the
number of Pre-Funded Warrants exercised in accordance with the terms and conditions of this Agency Agreement, (b) the instructions of each registered holder or Participant, as the case may be, with respect to delivery of the Pre-Funded Warrant
Shares issuable upon such exercise, and the delivery of definitive Warrant Certificates, as appropriate, evidencing the balance, if any, of the Pre-Funded Warrants remaining after such exercise, (c) in case of a Book-Entry Warrant Certificate, the
notation that shall be made to the records maintained by the Depository, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance, if any, of the Pre-Funded Warrants remaining after such exercise
and (d) such other information as the Company or such transfer agent and registrar shall reasonably require. 
 The Company shall, by 5:00
P.M., Philadelphia, Pennsylvania time, on the third business day next succeeding the Exercise Date of any Pre-Funded Warrant and the clearance of the funds in payment of the Exercise Price, execute, issue and deliver to the Warrant Agent the
Pre-Funded Warrant Shares to which such registered holder or Participant, as the case may be, is entitled, in fully registered form, registered in such name or names as may be directed by such registered holder or the Participant, as the case may
be. Upon receipt of such Pre-Funded Warrant Shares, the Warrant Agent shall, by 5:00 P.M., Philadelphia, Pennsylvania time, on the fifth Business Day next succeeding such Exercise Date, transmit such Pre-Funded Warrant Shares to or upon the order of
the registered holder or Participant, as the case may be. 
 In lieu of delivering physical certificates representing the Pre-Funded
Warrant Shares issuable upon exercise, provided the Company’s transfer agent is participating in the Depository’s Fast Automated Securities Transfer program, the Company shall use its reasonable best efforts to cause its transfer agent to
electronically transmit the Pre-Funded Warrant Shares issuable upon exercise to the Depository by crediting the account of the Depository or of the Participant through its Deposit Withdrawal Agent Commission system. The time periods for delivery
described in the immediately preceding paragraph shall apply to the electronic transmittals described herein. 

  
 4 

 3.2.3. Valid Issuance. All shares of Common Stock issued upon the proper exercise of a
Pre-Funded Warrant in conformity with this Agency Agreement shall be validly issued, fully paid and nonassessable. 
 3.2.4 Date of
Issuance. Each person in whose name any such certificate for shares of Common Stock is issued shall for all purposes be deemed to have become the holder of record of such shares on the date on which the Pre-Funded Warrant was surrendered and
payment of the Exercise Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed
to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open. 

3.2.5 Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Pre-Funded
Warrant Shares, the Company shall promptly issue to the registered holder the number of Pre-Funded Warrant Shares that are not disputed. 

4. Transfer and Exchange of Pre-Funded Warrants. 

4.1. Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Pre-Funded Warrant
upon the Warrant Register, upon surrender of such Pre-Funded Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Pre-Funded Warrant
representing an equal aggregate number of Pre-Funded Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Pre-Funded Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time
upon request. 
 4.2. Procedure for Surrender of Pre-Funded Warrants. Pre-Funded Warrants may be surrendered to the Warrant Agent,
together with a written request for exchange or transfer reasonably acceptable to Warrant Agent, duly executed by the registered holder thereof, or by a duly authorized attorney, and thereupon the Warrant Agent shall issue in exchange therefor one
or more new Pre-Funded Warrants as requested by the registered holder of the Pre-Funded Warrants so surrendered, representing an equal aggregate number of Pre-Funded Warrants; provided, however, that except as otherwise provided herein or in any
Book-Entry Warrant Certificate, each Book-Entry Warrant Certificate may be transferred only in whole and only to the Depository, to another nominee of the Depository, to a successor depository, or to a nominee of a successor depository; provided
further, however, that in the event that a Pre-Funded Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Pre-Funded Warrant and issue new Pre-Funded Warrants in exchange therefor until the Warrant
Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Pre-Funded Warrants must also bear a restrictive legend. Upon any such registration of transfer, the Company shall
execute, and the Warrant Agent shall countersign and deliver, in the name of the designated transferee a new Warrant Certificate or Warrant Certificates of any authorized denomination evidencing in the aggregate a like number of unexercised
Pre-Funded Warrants. 

  
 5 

 4.3. Fractional Pre-Funded Warrants. The Warrant Agent shall not be required to effect any
registration of transfer or exchange which will result in the issuance of a Warrant Certificate for a fraction of a Pre-Funded Warrant. 

4.4. Service Charges. A service charge shall be made for any exchange or registration of transfer of Pre-Funded Warrants, as negotiated
between Company and Warrant Agent. 
 4.5. Pre-Funded Warrant Execution and Countersignature. The Warrant Agent is hereby authorized
to countersign and to deliver, in accordance with the terms of this Agency Agreement, the Pre-Funded Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever required by the Warrant Agent, will supply
the Warrant Agent with Pre-Funded Warrants duly executed on behalf of the Company for such purpose. 
 5. Other Provisions Relating to
Rights of Holders of Pre-Funded Warrants. 
 5.1. Lost, Stolen, Mutilated, or Destroyed Pre-Funded Warrants. If any Pre-Funded
Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent shall, in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a new warrant (a “New
Warrant”), but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company.
Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of
a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Warrant Agent as a condition precedent to the Company’s obligation to issue the New Warrant. 

5.2. Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued
shares of Common Stock that will be sufficient to permit the exercise in full of all outstanding Pre-Funded Warrants issued pursuant to this Agency Agreement. 

6. Concerning the Warrant Agent and Other Matters. 

6.1. Concerning the Warrant Agent. The Warrant Agent: 
  

	 	i)	shall have no duties or obligations other than those set forth herein and no duties or obligations shall be inferred or implied; 

  

	 	ii)	may rely on and shall be held harmless by the Company in acting upon any certificate, statement, instrument, opinion, notice, letter, facsimile transmission, telegram or other document, or any security delivered to it,
and reasonably believed by it to be genuine and to have been made or signed by the proper party or parties; 

  

	 	iii)	may rely on and shall be held harmless by the Company in acting upon written or oral instructions or statements from the Company with respect to any matter relating to its acting as Warrant Agent; 

 

	 	iv)	may consult with counsel satisfactory to it (including counsel for the Company) and shall be held harmless by the Company in relying on the advice or opinion of such counsel in respect of any action taken, suffered or
omitted by it hereunder in good faith and in accordance with such advice or opinion of such counsel; 

  
 6 

	 	v)	solely shall make the final determination as to whether or not a Pre-Funded Warrant received by Warrant Agent is duly, completely and correctly executed, and Warrant Agent shall be held harmless by the Company in
respect of any action taken, suffered or omitted by Warrant Agent hereunder in good faith and in accordance with its determination; 

  

	 	vi)	shall not be obligated to take any legal or other action hereunder which might, in its judgment subject or expose it to any expense or liability unless it shall have been furnished with an indemnity satisfactory to it;
and 

  

	 	vii)	shall not be liable or responsible for any failure of the Company to comply with any of its obligations relating to the Registration Statement or this Agency Agreement, including without limitation obligations under
applicable regulation or law. 

 6.2 Payment of Taxes. Issuance and delivery of certificates for shares of Common Stock
upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be
paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than
that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. The Warrant Agent shall not
register any transfer or issue or deliver any Warrant Certificate(s) or Warrant Shares unless or until the persons requesting the registration or issuance shall have paid to the Warrant Agent for the account of the Company the amount of such tax, if
any, or shall have established to the reasonable satisfaction of the Company that such tax, if any, has been paid. 
 6.3 Resignation,
Consolidation, or Merger of Warrant Agent. 
 6.3.1. Appointment of Successor Warrant Agent. The Warrant Agent, or any successor
to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Warrant Agent becomes vacant by
resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in
writing of such resignation or incapacity by the Warrant Agent or by the holder of the Pre-Funded Warrant (who shall, with such notice, submit his Pre-Funded Warrant for inspection by the Company), then the holder of any Pre-Funded Warrant may apply
to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent (but not including the initial Warrant Agent), whether appointed by the
Company or by such court, shall be a corporation organized and existing under the laws of the State of Delaware, in good standing and having its principal office in the State of New York, and authorized under such laws to exercise corporate trust
powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant
Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any 

  
 7 

 
reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all
the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and
effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations. 

6.3.2. Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice
thereof to the predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment. 

6.3.3. Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be
consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agency Agreement without any further act. 

6.4. Fees and Expenses of Warrant Agent. 

6.4.1. Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration in an amount separately agreed to between
Company and Warrant Agent for its services as Warrant Agent hereunder and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder. One half of the total
Warrant Agent fees (not including postage) must be paid upon execution of this Agency Agreement. The remaining half must be paid within fifteen (15) business days thereafter. An invoice for any out-of-pocket and/or per item fees incurred will be
rendered to and payable by the Company within fifteen (15) days of the date of said invoice. It is understood and agreed that all services to be performed by Warrant Agent shall cease if full payment for its services has not been received in
accordance with the above schedule, and said services will not commence thereafter until all payment due has been received by Warrant Agent. 

6.4.2. Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed,
acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agency Agreement. 

6.5. Liability of Warrant Agent. 

6.5.1. Reliance on Company Statement. Whenever in the performance of its duties under this Agency Agreement, the Warrant Agent shall
deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be
deemed to be conclusively proved and established by a statement signed by the President of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant
to the provisions of this Agency Agreement. 

  
 8 

 6.5.2. Indemnity. The Warrant Agent shall be liable hereunder only for its own gross
negligence, willful misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, claims, losses, damages, costs and reasonable counsel fees, for anything done
or omitted by the Warrant Agent in the execution of this Agency Agreement except as a result of the Warrant Agent’s gross negligence, willful misconduct, or bad faith. 

6.5.3. Limitation of Liability. The Warrant Agent’s aggregate liability, if any, during the term of this Agency Agreement with
respect to, arising from, or arising in connection with this Agency Agreement, or from all services provided or omitted to be provided under this Agency Agreement, whether in contract, or in tort, or otherwise, is limited to, and shall not exceed,
the amounts paid or payable hereunder by the Company to Warrant Agent as fees and charges, but not including reimbursable expenses. 

6.5.4 Disputes. In the event any question or dispute arises with respect to the proper interpretation of this Agency Agreement or the
Warrant Agent’s duties hereunder or the rights of the Company or of any holder of a Pre-Funded Warrant, the Warrant Agent shall not be required to act and shall not be held liable or responsible for refusing to act until the question or dispute
has been judicially settled (and the Warrant Agent may, if it deems it advisable, but shall not be obligated to, file a suit in interpleader or for a declaratory judgment for such purpose) by final judgment rendered by a court of competent
jurisdiction, binding on all parties interested in the matter which is no longer subject to review or appeal, or settled by a written document in form and substance satisfactory to the Warrant Agent and executed by the Company and each other
interested party. In addition, the Warrant Agent may require for such purpose, but shall not be obligated to require, the execution of such written settlement by all the Pre-Funded Warrant holders, as applicable, and all other parties that may have
an interest in the settlement. 
 6.5.5 Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of
this Agency Agreement or with respect to the validity or execution of any Pre-Funded Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agency
Agreement or in any Pre-Funded Warrant; nor shall it be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the
existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agency
Agreement or any Pre-Funded Warrant or as to whether any shares of Common Stock will when issued be valid and fully paid and nonassessable. 

6.6. Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agency Agreement and agrees to perform the
same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Pre-Funded Warrants exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant
Agent for the purchase of shares of Common Stock through the exercise of Pre-Funded Warrants. 
 7. Miscellaneous Provisions. 

  
 9 

 7.1. Successors. All the covenants and provisions of this Agency Agreement by or for the
benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns. 
 7.2.
Notices. Any notice, statement or demand authorized by this Agency Agreement to be given or made by the Warrant Agent or by the holder of any Pre-Funded Warrant to or on the Company shall be sufficiently given when so delivered if by hand or
overnight delivery or if sent by certified mail or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows: 

Provectus Biopharmaceuticals, Inc. 

7327 Oak Ridge Highway, Suite A 

Knoxville, Tennessee 37931 

Attn: Timothy C. Scott 
 With a
copy to: 
 Baker, Donelson, Bearman, Caldwell & Berkowitz, PC 

211 Commerce Street, Suite 800 

Nashville, Tennessee 37201 

Attention: Lori B. Metrock, Esq. 

Any notice, statement or demand authorized by this Agency Agreement to be given or made by the holder of any Pre-Funded Warrant or by the
Company to or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five days after deposit of such notice, postage prepaid, addressed
(until another address is filed in writing by the Warrant Agent with the Company), as follows: 
 Broadridge Corporate Issuer Solutions,
Inc. 
 1717 Arch Street 

Suite 1300 
 Philadelphia,
Pennsylvania 19103 
 Attn: Compliance Department 

With a copy to: 
 Broadridge
Financial Solutions, Inc. 
 2 Journal Square Plaza 

Jersey City, New Jersey 07306 

Attention: General Counsel 

7.3. Applicable law. The validity, interpretation, and performance of this Agency Agreement and of the Pre-Funded Warrants shall be
governed in all respects by the laws of the State of Delaware, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action,
proceeding or claim against it arising out of or relating in any way to this Agency 

  
 10 

 
Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such
jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenience forum. Any such process or summons to be served upon the Company may be
served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 7.2 hereof. Such mailing shall be deemed personal service and shall be legal and
binding upon the Company in any action, proceeding or claim. 
 7.4. Persons Having Rights under this Agency Agreement. Nothing in
this Agency Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders of
the Pre-Funded Warrants, any right, remedy, or claim under or by reason of this Agency Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in
this Agency Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the Pre-Funded Warrants. 

7.5. Examination of the Agency Agreement. A copy of this Agency Agreement shall be available at all reasonable times at the office of
the Warrant Agent in the city of Philadelphia, Commonwealth of Pennsylvania, for inspection by the registered holder of any Pre-Funded Warrant. The Warrant Agent may require any such holder to submit his Pre-Funded Warrant for inspection by it. 

7.6. Counterparts. This Agency Agreement may be executed in any number of original or facsimile counterparts and each of such
counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 

7.7. Effect of Headings. The Section headings herein are for convenience only and are not part of this Agency Agreement and shall not
affect the interpretation thereof. 
 7.8 Amendments. This Agency Agreement may be amended by the parties hereto without the consent
of any registered holder for the purpose of curing any ambiguity, or of curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this
Agency Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the registered holders. All other modifications or amendments, including any amendment to increase the Exercise
Price or shorten the Exercise Period, shall require the written consent of the registered holders of a majority of the then outstanding Pre-Funded Warrants. 

7.9 Severability. This Agency Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision
hereof shall not affect the validity or enforceability of this Agency Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be
added as a part of this Agency Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable. 

  
 11 

 7.10 Force Majeure. In the event either party is unable to perform its obligations under
the terms of this Agency Agreement because of acts of God, strikes, failure of carrier or utilities, equipment or transmission failure or damage that is reasonably beyond its control, or any other cause that is reasonably beyond its control, such
party shall not be liable for damages to the other for any damages resulting from such failure to perform or otherwise from such causes. Performance under this Agency Agreement shall resume when the affected party or parties are able to perform
substantially that party’s duties. 
 7.11 Consequential Damages. Notwithstanding anything in this Agency Agreement to the
contrary, neither party to this Agency Agreement shall be liable to the other party for any consequential, indirect, special or incidental damages under any provision of this Agency Agreement or for any consequential, indirect, punitive, special or
incidental damages arising out of any act or failure to act hereunder even if that party has been advised of or has foreseen the possibility of such damages. 

[Signature Page Follows.] 

  
 12 

 IN WITNESS WHEREOF, this Agency Agreement has been duly executed by the parties hereto as of the
day and year first above written. 
  

			
	 PROVECTUS BIOPHARMACEUTICALS,
INC.

 
			
		
	By:	 	 

 
			
	Name:	 	John R. Glass
	Title:	 	Interim Chief Financial Officer

  

			
	BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC.

 
			
		
	By:	 	 

 
			
	 Name:
	 	
	 Title:
	 	

 [Signature page to Warrant Agency Agreement] 

  
 13 

 EXHIBIT A 

Form of Pre-Funded Warrant 

[Attached.] 

  
 Exhibit AEX-4.4

 Exhibit 4.4 

PROVECTUS BIOPHARMACEUTICALS, INC. 

WARRANT TO PURCHASE COMMON STOCK 

Number of Shares:                 

(subject to adjustment) 
  

			
	Warrant No.            	  	Original Issue Date: January     , 2017

 Provectus Biopharmaceuticals, Inc., a
Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
                or its permitted registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up
to a total of             shares of common stock, $0.001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and
all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.0025 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), upon
surrender of this warrant to purchase Common Stock (including any warrants to purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof
(the “Original Issue Date”) and through and including 5:00 PM Eastern Time on the date that is five years following the Original Issue Date (the “Expiration Date”), subject to the extension of the Expiration Date as
set forth in Section 4(a) and subject to the following terms and conditions: 
 1. Definitions. For purposes of this Warrant, the
following terms shall have the following meanings: 
 (a) “Affiliate” of any Person means any other Person directly or
indirectly controlling, controlled by or under common control with such Person. 
 (b) “Commission” means the United States
Securities and Exchange Commission and any successor entity thereto. 
 (c) “Closing Sale Price” means, for any security as
of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not
designate the last trade price, then the last trade price of such security immediately prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the
over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if no last trade price is reported for such
security by Bloomberg Financial Markets, the average of the bid and ask prices, of any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value of such security on such date. The Board of Directors’ determination shall be binding upon all
parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. 

(d) “Person” means any natural person, corporation, firm, joint venture, partnership, limited liability company, association,
enterprise, trust or other entity or organization, or any government or political subdivision or any agency, department or instrumentality thereof. 

(e) “Principal Trading Market” means the trading market on which the Common Stock is primarily quoted for trading, and which,
as of the Original Issue Date shall be the OTCQB. 
 (f) “Securities Act” means the Securities Act of 1933, as amended.

 (g) “Trading Day” means a day on which the Principal Trading Market is open for trading. 

 2. Registration of Warrants. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is permissibly
assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary. 
 3. Registration of Transfers. Subject to compliance with all applicable securities laws, the
Company shall register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment of all applicable transfer taxes. Upon any such registration of transfer, a new warrant to purchase Common
Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of
this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the
New Warrant that the Holder had in respect of this Warrant. The Company shall prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3. Until due presentment for registration of
transfer, the Company may treat the registered Holder hereof as the owner and holder of this Warrant for all purposes, and the Company shall not be affected by any notice to the contrary. 

4. Exercise and Duration of Warrants. 

(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from
time to time on or after the Original Issue Date and through and including 5:00 PM Eastern Time on the Expiration Date; provided, however, that, if upon the Expiration Date, the Holder’s exercise in full of this Warrant would cause the
Holder’s beneficial ownership of the Common Stock to exceed the Maximum Percentage, the term of this Warrant shall be automatically extended until, and this Warrant shall be automatically exercised on, the date that is the 90th day following
the date on which this Warrant may be exercised in full without the Holder exceeding the Maximum Percentage. Subject to the foregoing sentence, at 5:00 PM Eastern Time on the Expiration Date, the portion of this Warrant not exercised prior thereto
shall be void and of no value and this Warrant shall terminate and no longer be outstanding. 
 (b) The Holder may exercise this Warrant by
delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares
as to which this Warrant is being exercised (which may take the form of a “net share exercise” if so indicated in the Exercise Notice pursuant to Section 10 below), and the date on which the last of such items is
delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” If held in certificated form, the Holder shall be required to deliver the original Warrant (the “Warrant
Certificate”) in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the Warrant Certificate and issuance of a New Warrant to the Holder evidencing its right to
purchase the remaining number of Warrant Shares. For the avoidance of doubt, the Company may not substitute, and the Holder may not request, a cash payment in satisfaction of the Company’s obligation to issue and deliver Warrant Shares pursuant
to an Exercise Notice. 
 5. Delivery of Warrant Shares. 

(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise
Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The Depository Trust Company
(“DTC”) through its Deposit Withdrawal Agent Commission system, or if the Company’s transfer agent is not participating in the Fast Automated Securities Transfer Program (the “FAST Program”) or if the
certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the
name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any Person permissibly so designated by the Holder to receive Warrant Shares, shall be deemed to
have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares,
as the case may be. 

  
 2 

 (b) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant
Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same,
any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the
Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the
Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. 

6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided,
however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an
Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. 

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s
obligation to issue the New Warrant. 
 8. Reservation of Warrant Shares. The Company covenants that it will at all times while this
Warrant is outstanding reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein
provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account
the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly and validly authorized and issued, and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be
issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. 

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to
adjustment from time to time as set forth in this Section 9. 
 (a) Stock Dividends and Splits. If the
Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides its
outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of
capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the 

  
 3 

 
numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution,
provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and
thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the
effective date of such subdivision or combination. 
 (b) Pro Rata Distributions. If the Company, at any time while this Warrant is
outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph) or (iii) rights or
warrants to subscribe for or purchase any security, or (iv) any other asset (in each case, “Distributed Property”), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of
stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled
to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. 

(c) Fundamental Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or
consolidation of the Company with or into another Person, in which the Company is not the surviving entity or the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the
voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one or a series of related transactions, (iii) pursuant
to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock who tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as
applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company or (v) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of
shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the
same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant
Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction in which the Company
is not the surviving entity or the Alternate Consideration includes securities of another Person unless prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser
of assets of the Company) shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. 

(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to paragraph (a) of this
Section 9, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for
the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. 

(e) Calculations. All calculations under this Section 9 shall be made to the nearest cent or the nearest
whole share, as the case may be. For purposes of this Section 9, any calculation of the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall not include treasury shares, if any.
Notwithstanding anything to the contrary in this Section 9, no adjustment in the Exercise Price shall be required 

  
 4 

 
unless such adjustment would require an increase or decrease of at least 1% in such price; provided, however, that any adjustments which by reason of the immediately preceding
sentence are not required to be made shall be carried forward and taken into account in any subsequent adjustment. 
 (f) Notice of
Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with
the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as
applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder. 

(g) Notice of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii) authorizes or approves, enters into any material definitive agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the
affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction
at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to
deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, if the Company enters into any material definitive agreement
contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), the Company shall deliver to the Holder a notice
of such Fundamental Transaction at least fifteen (15) days prior to the date such Fundamental Transaction is consummated. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any of its subsidiaries, the Holder shall keep such information confidential until the Company shall file such notice with the Commission pursuant to a Current
Report on Form 8-K. 
 10. Payment of Exercise Price. Notwithstanding anything contained
herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “net share exercise”, in which event the Company shall issue to the Holder the number of Warrant Shares determined
as follows: 
 X = Y [(A-B)/A] 

where: 
  

	“X”	equals the number of Warrant Shares to be issued to the Holder; 

	“Y”	equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; 

	“A”	equals the average of the Closing Sale Prices of the shares of Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the Exercise Date; and 

	“B”	equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. 

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a
“cashless exercise” transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the
Commission continues to take the position that such treatment is proper at the time of such exercise). 
 If Warrant Shares are issued in
such a cashless exercise, the Company acknowledges and agrees that, in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised and the Company agrees not
to take any position contrary to this Section 10. 

  
 5 

 11. Limitations on Exercise. The Company shall not affect the exercise of any portion of
this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, to the extent that after giving effect to such exercise, the Holder (together with the Holder’s Affiliates, and any persons acting as a group
together with the Holder or any Holder’s Affiliates) would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the Common Stock outstanding immediately after giving effect to such exercise. For purposes of the
foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and its Affiliates, and any persons acting as a group together with the Holder and the Holder’s Affiliates, shall include the number of Warrant
Shares with respect to which the determination of such sentence is being made, but shall exclude Warrant Shares which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder and
its Affiliates, and any persons acting as a group together with the Holder and the Holder’s Affiliates, and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by
the Holder and its Affiliates, and any persons acting as a group together with the Holder and the Holder’s Affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on
conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”). The Company shall not be responsible for calculating beneficial ownership in accordance with the provisions of this Section 11. To the extent that the
limitation contained in this Section 11 applies, the Holder’s submission of an Exercise Notice shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to any other
securities owned by the Holder together with any Affiliates, and any persons acting as a group together with the Holder and the Holder’s Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Maximum
Percentage, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
the most recent of (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public
filing with the Commission, as the case may be, (2) a more recent written public announcement by the Company, or (3) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. For
any reason at any time, upon the written or oral request of the Holder, the Company shall within three (3) Trading Days confirm to the Registered Holder the number of shares of Common Stock then outstanding. In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and its Affiliates, and any persons acting as a group together with the
Holder and the Holder’s Affiliates, since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant and the provisions of this Section 11 shall continue to
apply; provided that (y) any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company, and (z) any such increase or decrease will apply only to the Holder. For purposes of
clarity, the Common Stock underlying this Warrant in excess of the Maximum Percentage for the Holder shall not be deemed to be beneficially owned by that Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. The provisions set forth herein shall be construed and implemented in a manner otherwise than in strict conformity with the other terms of this Section 11
to the extent necessary to correct any such provision which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. 
 12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant.
In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number. 

13. Warrant Agent. Broadridge Corporate Issuer Solutions, Inc., is acting as the warrant agent under this Warrant and is also the
transfer agent for the Common Stock (the “Warrant Agent”). 
 14. Notices. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the 

  
 6 

 
date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail at the facsimile number or e-mail address specified in the books and records of the Company prior to 5:00 PM Eastern Time on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is
delivered via facsimile or confirmed e-mail at the facsimile number or e-mail address specified in the books and records of the Company on a day that is not a Trading
Day or later than 5:00 PM Eastern Time on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt
by the Person to whom such notice is required to be given, if by hand delivery. 
 15. Miscellaneous. 

(a) No Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this
Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In
addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are
asserted by the Company or by creditors of the Company. 
 (b) Authorized Shares. 

(i) Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,
(b) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. 

(ii) Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in
the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 

(c) Successors and Assigns. Subject to the restrictions on transfer set forth in this Warrant and compliance with applicable securities
laws, this Warrant may be assigned by the Holder. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall
be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. 

(d) Amendment and Waiver. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder. 
 (e) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all
of the terms and conditions contained herein. 
 (f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION,
VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE 

  
 7 

 
GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY
IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. 

(g) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. 
 (h) Severability. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. 

[Signature Page Follows.] 
  

  
 8 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. 

			
	PROVECTUS BIOPHARMACEUTICALS, INC.
		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

 [Signature Page to Warrant] 

  
 9 

 Schedule 1 

NOTICE OF EXERCISE 
  

	TO:	PROVECTUS BIOPHARMACEUTICALS, INC. 

 The undersigned Holder hereby exercises the right to
purchase             shares of Common Stock (“Warrant Shares”) of Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), evidenced by
Warrant No.             (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant. 

1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as: 

a “cash exercise” with respect to             Warrant
Shares; and/or 
 a “net share exercise” pursuant to Section 10 of the Warrant with respect to
            Warrant Shares. 
 Warrant Shares shall be issued in
the name of the undersigned Holder or in such other name as is specified below: 
 2. Payment of Exercise Price: Cash Exercise. In
the event that the Holder has elected a “cash exercise” with respect to some or all of the Warrant Shares, the Holder shall pay the Exercise Price in the sum of $             to
the Company in accordance with the terms of the Warrant. 
 3. Payment of Exercise Price: Net Share Exercise. I n the event that the
Holder has elected a net share exercise with respect to some or all of the Warrant Shares, the Holder represents and warrants that the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg Financial Markets) for
the five (5) consecutive Trading Days ending on the date immediately preceding the Exercise Date is $            . The calculation of the number of Warrant Shares to be issued in
accordance with Section 10 of the Warrant is as follows: 
 4. Delivery of Warrant Shares. The Company shall cause the Warrant
Agent to deliver to Holder, or its designee or agent as specified above,             shares of Common Stock in respect of the exercise contemplated hereby. The Warrant Shares shall be
delivered to the following DWAC Account Number or by physical delivery of a certificate to: 
 Date:
                     
  

			
	Name of Registered Holder
		
	By: 	 	 
	Name:	 	  

	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]